Robotic Microsurgery System Gains CE Mark for Clinical Use in Europe

Microsure (Eindhoven, The Netherlands) announced on May 7, 2026 that its MUSA-3 system received CE mark approval, enabling clinical use in Europe. The milestone marks the company’s transition from product development to a clinical medical device business focused on evidence generation and adoption. Microsure develops high‑precision, robot‑assisted systems for microsurgery.

MUSA-3 is designed to assist surgeons during open super‑microsurgical procedures by downscaling and stabilizing hand movements. The system is intended to support super‑micro‑anastomosis on small anatomical structures such as lymphatic ducts, blood vessels, and nerves. Stated applications include free flap surgery, lymphatic surgery, and peripheral nerve surgery.

With the CE mark secured, the company will now focus on generating clinical evidence at leading European centers, strengthening clinical partnerships, and demonstrating how robotic assistance can support surgeons in super-microsurgical procedures. Looking ahead, the organization aims to advance clinical adoption and build the foundation for broader commercialization.

This next phase is also accompanied by a leadership transition intended to support clinical execution. The appointment of Alex Joseph as CEO reflects that shift. Having played a central role in the development of MUSA-3, he brings extensive experience in surgical robotics, clinical settings, and regulated medical device development.

“As I step into the role of CEO, Microsure is entering a new phase. With the CE mark now achieved, our focus is on generating clinical evidence and demonstrating the value of our technology in practice,” said Alex Joseph, Chief Executive Officer, Microsure.

Related Links
Microsure